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Abstract
Background: Some animal studies have reported that Achillea millefolium (A. millefolium) extract can affect intestinal movements
in rats. However, no study is available on the effect of A. millefolium on recovery from gastroenteritis in human subjects.
Objectives: This study aimed to investigate the effect of A. millefolium on recovery from gastroenteritis in patients over 12 years old.
Patients and Methods: A randomized controlled trial was conducted on 44 patients with gastroenteritis. The patients were ran-
domly assigned to two groups of 22 each. The control group received the usual treatments. In addition to the usual treatments,
the intervention group received 0.5 mL/kg of A. millefolium distillate every 8 hours. The duration of recovery was recorded for both
groups. Descriptive statistics, Chi-square, Fisher’s exact test, and the t-test were used to compare the two groups.
Results: The mean duration of recovery in the group receiving A. millefolium distillate was 1.31± 0.71 days, while it was 1.86± 0.71
days in the control group (P = 0.015).
Conclusions: Adding A.millefolium distillate to the usual treatment for simple gastroenteritis was effective in shortening the recov-
ery time.
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1. Background
Acute gastroenteritis is a major public health problem
and one of the most common diseases worldwide (1). Ac-
cording to the world health organization (WHO), about 2
billion cases of diarrheal disease occur annually (2).
Symptoms of gastroenteritis may be self-limiting or
may require medication to resolve. The main symptoms
may include fever, abdominal pain, lethargy, diarrhea, and
vomiting, which can cause electrolyte imbalance, dehydra-
tion, and shock (3-7). Medical and nursing treatments usu-
ally include monitoring intake and output, oral or intra-
venous fluids, and electrolyte replacement (8); administra-
tion of zinc (1, 3, 6, 9, 10); oral or intravenous antiemetic
medications, such as ondansetron (3, 4); and antibiotics
in bacterial cases (11, 12). Such treatments may have side
effects; for example, ondansetron may increase the fre-
quency of diarrhea (13). Excessive use of antibiotics might
also increase the cost of treatment, lead to bacterial resis-
tance, and prolong the diarrhea (14, 15).
Due to the side effects of synthetic drugs, herbal reme-
dies are increasingly used, which also have lower costs
and better patient compliance (16). One of the plants that
has been commonly used is yarrow, or Achillea millefolium,
which belongs to the asteraceae family. This herb is tra-
ditionally used to treat abdominal pain, stomach pain,
acute gastritis, wounds, and uncomplicated diarrhea (17,
18). It contains certain active ingredients, such as camphor,
1 and 8-cineol, borneol, and β-pinene (17), which are used
for medicinal properties including anti-inflammatory, an-
tioxidant, anti-spasmodic, anti-hemorrhoidal, and disin-
fectant effects (19). Despite the historical background of
using A. millefolium and reports on its antiviral (19), anti-
inflammatory (20, 21), antibacterial (22, 23), and antispas-
modic (24) effects, studies about its application for the
treatment of diarrhea are rare.
In a study on the antispasmodic effects of A.millefolium,
Moradi et al. reported that its alcoholic extracts could in-
hibit the acetylcholine and KCL-induced contractions in
the smooth muscles of isolated ileum in rats (24). In an in
vitro study, it was reported that the extract of Achillea had
antirotaviral activity (19). Borrelli et al. have also reported
that A. millefolium aqueous extract can affect and normal-
ize contractions in mouse and human stomachs (25). In
a study on the antidiarrheal effect of a methanolic extract
of A. millefolium in rats, Bais et al. (26) attributed such ef-
fects to decreased bowel movements and support of the in-
testinal mucus against chemical changes (25). Another re-
cent study showed that a mouthwash solution containing
A. millefolium distillate could reduce the severity of stom-
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atitis in cancer patients undergoing chemotherapy (20). In
local observations, the first researcher has observed that
people in Lorestan Province, Iran, have traditionally used
boiled A. millefolium to treat or relieve diarrhea.
2. Objectives
This study aimed to investigate the effect of A. mille-
folium on recovery time from gastroenteritis.
3. Patients and Methods
This randomized controlled trial was conducted on
gastroenteritis patients referred to Shahid Beheshti med-
ical center and an infectious specialist’s office in Kashan,
Iran, over a six-month period during the year 2015.
The sample size was calculated using the results of a
pilot study on two groups (five patients each) with simple
gastroenteritis. The first group received A. millefolium dis-
tillate similar to that used in the present study, and the sec-
ond group received routine treatment. In the group that
received A. millefolium distillate, the mean recovery time
was 1.20±0.55 days, while it was 2.0±0.70 days in the sec-
ond group. Consequently, the sample size was determined
to be 19 patients in each group [α = 0.05, β = 0.1]. However,
we recruited 22 patients for each group to compensate for
probable attritions.
The inclusion criteria were age over 12 years, a diagno-
sis of simple gastroenteritis, the ability to eat by mouth,
lack of sensitivity to any herbal products (i.e. herbal drugs
and foods), lack of asthma or allergic rhinitis, willing-
ness to participate in the study, and lack of any other co-
morbidity, such as heart disease, diabetes, malabsorption,
coagulopathy, or eczema.
The exclusion criteria were receiving an order of noth-
ing by mouth during the study, the patient’s decision to
withdraw from the study, any incident requiring specific
treatments, the use of herbal remedies other than A. mille-
folium distillate, intolerance to A. millefolium (i.e. vomiting
immediately after ingestion), using any antidiarrheal diet,
developing an allergy to A.millefolium, and irregular use or
overuse of A. millefolium distillate.
On arrival, all patients were visited by a specialist in in-
fectious diseases or a general practitioner, and those meet-
ing the inclusion criteria were recruited. A total of 44 such
patients were consecutively recruited and randomly as-
signed to the study groups.
3.1. Intervention
The usual treatment consisted of oral rehydration ther-
apy and antiemetic medications, such as oral ondansetron
(4 mg every 8 hours), metoclopramide tablets (10 mg at
the time of nausea), and antispasmodic drugs, such as
hyoscine tablets (20 mg) or dicyclomine (20 mg). In bac-
terial cases, oral antibiotics, such as metronidazole (250
mg every 8 hours) or oral Bactrim (400 mg every 12 hours),
were also used.
The control group received the usual treatment. In ad-
dition to the usual treatment, the intervention group re-
ceived 0.5 mL/kg of A. millefolium distillate every 8 hours
(40 ppm concentration, purchased from Gol Joush Phar-
maceutical Co., Tabriz, Iran). The pasteurized A. millefolium
distillate was prepared in 120 mL dark glass bottles. Three
bottles of A. millefolium distillate were given to each pa-
tient in the intervention group at the end of the physi-
cian’s visit, and the patients were instructed to drink the
prescribed dosage of A. millefolium distillate before each
meal (i.e. every 8 hours), with a glass of water. They also
were instructed to discontinue use of the distillate and to
inform the physician or the first researcher if they could
not tolerate it, or if any symptoms appeared, such as itch-
ing, burning, or rash. The patients paid nothing for the A.
millefolium distillate. The outpatients carried out the pre-
scribed treatment at home and followed up through tele-
phone calls for three days. The hospitalized patients were
treated at the hospital and assessed through daily visits by
the same nurse.
All patients in both groups were instructed to rest un-
til recovery, and to not take any other medications. They
were also instructed to eat a regular diet but to not use fatty
or sweet foods for at least three days. The hospitalized pa-
tients received the regular hospital diet.
3.2. Data Collection
A two-part instrument was used. The first part included
demographic information, such as age, gender, education
level, living location, and financial status. There were also
questions on the severity of diarrhea at admission (mild: 3
- 5 times/day, moderate: 6 - 9 times/day, and severe: ≥ 10
times/day), whether they had a high fever on arrival (body
temperature < 38°C), the date of admission, and the names
and dosages of the drugs prescribed.
The second part of the questionnaire was a form con-
sisting of two questions about the duration of the disease,
from the initiation of diarrhea or vomiting to the time of
admission, and the number of days until complete recov-
ery (i.e. normal defecation < 3 times/day). The first part of
the instrument was completed upon the patient’s arrival
and the second section was completed through daily vis-
its or telephone calls for three successive days. All patients
and the nurse who assessed their recovery were blinded to
the type of treatment each patient was receiving.
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3.3. Ethical Considerations
This study was approved by the institutional review
board and research ethics committee of Kashan University
of Medical Sciences (ethics code: IR.KAUMS.REC.1394.55, is-
sued on 06.07.2015). All of the patients were briefed on the
study’s aims, without specification of the exact type of in-
tervention they may receive. They also were assured about
the voluntary nature of their participation, their right to
withdraw from the study at any point, and data confiden-
tiality. All of the subjects signed written informed consent
before participation. The research team was careful to pre-
serve the participants’ rights according to the Helsinki eth-
ical declaration.
3.4. Data Analysis
Data were analyzed using SPSS version 13. Descriptive
statistics were used to describe the data. Chi-square and
Fisher’s exact tests were used to compare the two groups
in terms of nominal and categorical variables, such as gen-
der, education level, economic status, place of residence,
the drugs used, and the presence of a high fever or abdom-
inal cramps at arrival. The Kolmogorov-Smirnov test was
performed to examine the normality of the quantitative
variables. The age distribution was normal, but the distri-
bution of the duration of symptoms before admission, the
recovery duration, and the doses of the drugs used were
not normal. Next, the t-test was used to compare the mean
age of the two groups, and the Mann-Whitney U test was
used to compare the duration of disease before admission,
the mean duration of recovery, and the mean dose of drugs
used in the two groups. A P value < 0.05 was selected as the
significance level for all tests.
4. Results
A total of 44 patients with a mean age of 28.62± 2.20
years participated in this study. No significant differences
were observed between the two groups in terms of per-
sonal and clinical characteristics, including the severity of
diarrhea (Table 1). However, a significant difference was ob-
served between the mean recovery time in the two groups
(P = 0.015) (Table 2). No allergic reaction to A. millefolium
was observed during the study and no attrition occurred
in the study sample.
Table 3 shows the usual drugs used over the course of
treatment in the two groups. The amount of antiemetic
drugs used was higher in the control group. However,
in terms of antibiotics, the amount of metronidazole
was higher in the control group, while Bactrim was used
more in the intervention group. Moreover, the amount of
hyoscine was higher in the intervention group, while dicy-
clomine was used more in the control group.
Table 1. Personal Characteristics of Intervention and Control Groupsa
Variable Group P Value
Intervention Control
Gender 0.220b
Male 7 (31.8) 11 (50)
Female 15 (68.2) 11 (50)
Fever 0.741b
Yes 6 (27.3) 7 (31.8)
No 16 (72.7) 15 (68.2)
Living location 0.457c
Urban 19 (86.4) 16 (72.7)
Rural 3 (13.6 6 (27.3)
Education level 0.838c
Illiterate 3 (13.6) 2 (9.1)
Semiliterate 10 (45.5) 9 (40.9)
High school and over 9 (40.9) 11 (50)
Economic status 0.99c
Sufficient 19 (86.4) 18 (81.8)
Insufficient 3 (13.6) 4 (18.2)
Drugs used 0.101
All of the drugs 12 (54.5) 14 (63.6)
Antiemetics 5 (22.7) 8 (36.4)
None 4 (18.2) 0
Abdominal cramps 0.233c
Yes 22 (100) 19 (86.4)
No 0 3 (13.6)
Severity of diarrhea 0.538b
Mild 6 (27.3) 3 (13.6)
Moderate 9 (40.9) 12 (54.5)
Severe 7 (31.8) 7 (31.8)
Age, y (mean± SD) 29.22± 3.04 28.51± 3.37 0.874d





To the best of our knowledge, this was the first study
on the effect of A. millefolium distillate on gastroenteritis
in a sample of human subjects. In this study, the mean du-
ration of recovery was significantly shorter in the group
receiving A. millefolium distillate. This effect might be at-
tributed not only to the disinfectant properties of Achil-
lea’s active ingredients but also to its antispasmodic ef-
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Table 2. Comparison of Mean Duration of Symptoms Before Admission and Mean
Recovery Time
Variable Group P Value
Intervention Control
Duration of symptoms before
admission, days
1.77± 0.81 1.54± 0.67 0.603
Duration of recovery, days 1.31± 0.71 1.86± 0.71 0.001
Table 3. Comparison of Drugs Useda
Drug, mg Group P Value
Control Intervention
Metronidazole 863.63± 993.21 272.72± 455.84 0.027
Co-trimoxazole 145.45± 486.70 436.36± 739.72 0.080
Ondansetron 9.09± 11.65 5.45± 6.23 0.615
Metoclopramide 15.45± 21.54 4.09± 10.53 0.019
Hyoscine 9.09± 11.91 15.90± 21.74 0.314
Dicyclomine 12.72± 23.33 2.72± 8.82 0.062
Diphenoxilate 0 0.77± 2.72 0.153
aValues are expressed as mean± SD.
fects, which cause decreased bowel movements. Although
no significant differences were observed between the two
groups with regard to the antibiotics received, the amount
of antiemetic drugs used was significantly higher in the
control group. This finding might also be attributed to
the beneficial effects of A.millefoliumdistillate on vomiting
due to gastroenteritis. An animal study also reported that
alcoholic extract of A. millefolium could inhibit the smooth
muscle contractions of isolated ileums in rats (24). Bais et
al. have also reported that methanolic extract of A. mille-
folium showed antidiarrheal activity in rats (26). Some pre-
vious studies have also reported that A. millefolium has an-
tiviral (19) and antibacterial (24) effects, which might also
have contributed to the shorter recovery time of the pa-
tients in the intervention group.
When considering the results of this study, some lim-
itations should be kept in mind. Firstly, this was the first
human-subject study using A. millefolium distillate for gas-
troenteritis, and the study was conducted on a small sam-
ple, which might limit the generalizability of the findings.
In addition, we did not perform any laboratory examina-
tions to exactly distinguish between viral and bacterial di-
arrhea. The present study was conducted on a mix of hos-
pitalized and outpatient subjects. There was telephone
follow-up for the outpatients; however, monitoring their
strict adherence to medical advice was not possible. Given
these limitations, further studies with larger sample sizes
are recommended. Finally, studies to identify the exact
active ingredients that are effective against diarrhea and
vomiting are suggested.
The present study showed that adding A. millefolium
distillate to the usual treatments for simple gastroenteritis
was effective in reducing the time of recovery. We observed
no side effects in the patients during this study. Adding
A. millefolium distillate to the usual treatments for simple
cases of gastroenteritis can therefore be recommended.
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